Hindustantimes wants to start sending you push notifications. Click allow to subscribe

Cadila jab immunogenic, safe: Phase 1 trial data

None of the 48 participants experienced any serious adverse events. However, at least 12 participants reported an adverse event.
By Anonna Dutt, Hindustan Times, New Delhi
PUBLISHED ON JUL 24, 2021 02:07 AM IST
The phase I trial, however, had no women participants.(Reuters file photo. )

The DNA vaccine, developed by Indian pharmaceutical company Zydus Cadila, has been found to be safe and immunogenic, according to the 48-participant phase I trial published ahead of print on EClinicalMedicine journal by Lancet. There were no vaccine-related severe adverse events reported and the three-dose vaccine was found to generate good antibody and cellular immunity, the study said.

The phase I trial, however, had no women participants.

The 48 participants were divided into four study arms study two different doses and two different methods of vaccine administration; arm 1 received 1mg dose of the vaccine using needle, arm 2 received 1 mg vaccine intradermally, arm 3 received 2 mg vaccine with needle, and arm 4 received 2 mg vaccine intradermally.

None of the 48 participants experienced any serious adverse events. However, at least 12 participants reported an adverse event. The “solicited” adverse events that were seen in seven of the participants were mild fever, itching, joint pain, tenderness of injection site, and moderate diarrhoea. Most of the events were reported after the administration of the first dose of the vaccine

RELATED STORIES
SHARE THIS ARTICLE ON
This site uses cookies

This site and its partners use technology such as cookies to personalize content and ads and analyse traffic. By using this site you agree to its privacy policy. You can change your mind and revisit your choices at anytime in future.

OPEN APP